Finance

Lists
Q2 2026 earnings • released • EPS miss -14.29%
See results
PYXS:NASDAQ
Pyxis Oncology Inc
$2.95
-1.99%
(-0.060) 1D
Aug 17, 10:47:16 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PYXS...
Open
$3.03
High
$3.03
Low
$2.83
Mkt. cap
246.05M
Avg. vol.
1.45M
Volume
158.40K
52-wk high
$5.55
52-wk low
$1.03
EPS
-$1.40
Beta
1.31
Shares outstanding
83.41M
No. of employees
56
Open
$3.03
High
$3.03
Low
$2.83
Mkt. cap
246.05M
Avg. vol.
1.45M
Volume
158.40K
52-wk high
$5.55
52-wk low
$1.03
EPS
-$1.40
Beta
1.31
Shares outstanding
83.41M
No. of employees
56
About Pyxis Oncology Inc
CEO-
Employees56
Founded2018
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitepyxisoncology.com
Analyst ratings
Based on 8 analysts giving stock ratings to PYXS in the past 3 months
Strong buy
Buy
7
Hold
1
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for PYXS in the last 3 months.
Highest
Current $2.95
$12.00 (+306.78%)
Average
$7.29 (+147.12%)
Lowest
$5.00 (+69.49%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sam Slutsky
LifeSci Capital
Buy
Maintained
$6.00
+103.4%
08/14/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$5.00
+69.5%
08/13/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$6.00
+103.4%
08/14/2026
Derek Archila
Wells Fargo
Buy
Reiterated
$12.00
+306.8%
08/14/2026
Andy Hsieh
William Blair
Hold
Maintained
-
-
08/13/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
$7.00
+137.3%
07/06/2026
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$8.00
+171.2%
07/02/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$7.00
+137.3%
06/29/2026
Last report
Aug 13, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.40 / -$0.35
-14.29%miss
Revenue / Est. (USD)
- / 22.22K
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
11.04M
-
-
Cost of goods sold
-
2.39M
-
-
Cost of revenue
-
2.39M
-
-
Research and development expenses
17.81M
21.71M
19.98M
16.06M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.97M
4.54M
3.75M
9.54M
Operating expense
22.78M
26.25M
23.73M
25.60M
Total operating expenses
22.78M
28.64M
23.73M
25.60M
Operating income
-22.78M
-17.60M
-23.73M
-25.60M
Other non operating income
-
-
-
-
EBT including unusual items
-22.00M
-17.00M
-23.27M
-25.35M
EBT excluding unusual items
-22.00M
-17.00M
-23.27M
-25.35M
Income tax expense
-
1.10M
-
-
Effective tax rate
-
-6.49%
-
-
Other operating expenses
-
-
-
-
Net income
-22.00M
-18.11M
-23.27M
-25.35M
Net profit margin
-
-164.03%
-
-
Earnings per share
-0.35
-0.29
-0.37
-0.40
Interest and investment income
774.00K
600.00K
457.00K
255.00K
Interest expense
-
-
-
-
Net interest expenses
774.00K
600.00K
457.00K
255.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-22.25M
-14.71M
-23.27M
-25.30M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps